Approval · Notice of Compliance 3763 · 2004
DIOVAN: Notice of Compliance 3763
Issued June 11, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3763
- Date
- June 11, 2004
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the indications and clinical use section of the product monograph for the use of valsartan as first-line therapy
- Therapeutic class
- Angiotensin II at1 receptor blocker
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIOVAN | Not yet assigned | — |